BIIB107
/ Biogen
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
September 27, 2025
Dose Optimization of BIIB107, an Anti-Alpha-4 Integrin Monoclonal Antibody, Through Population Pharmacokinetic and Pharmacodynamic Modeling.
(PubMed, J Clin Pharmacol)
- P1 | "Simulations showed that 450 mg SC every 8 weeks maintained sustained α4 integrin saturation ≥70%, the therapeutic threshold for efficacy, supporting this regimen for investigation in MS patients. These findings emphasize the value of model-informed drug development in optimizing therapeutic monoclonal antibody doses and support BIIB107's further clinical advancement."
Journal • PK/PD data • CNS Disorders • Multiple Sclerosis • ITGA4
April 15, 2024
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=84 | Completed | Sponsor: Biogen | Active, not recruiting ➔ Completed
Trial completion
November 03, 2023
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=84 | Active, not recruiting | Sponsor: Biogen | Recruiting ➔ Active, not recruiting | Trial completion date: Oct 2023 ➔ Mar 2024 | Trial primary completion date: Oct 2023 ➔ Mar 2024
Enrollment closed • Trial completion date • Trial primary completion date
October 12, 2022
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=76 | Recruiting | Sponsor: Biogen | Trial completion date: Feb 2023 ➔ Oct 2023 | Trial primary completion date: Feb 2023 ➔ Oct 2023
Trial completion date • Trial primary completion date
April 19, 2022
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=78 | Recruiting | Sponsor: Biogen | Trial completion date: Oct 2022 ➔ Feb 2023 | Trial primary completion date: Oct 2022 ➔ Feb 2023
Trial completion date • Trial primary completion date
February 08, 2022
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=78 | Recruiting | Sponsor: Biogen | Trial completion date: Dec 2021 ➔ Oct 2022 | Trial primary completion date: Dec 2021 ➔ Oct 2022
Trial completion date • Trial primary completion date
January 11, 2021
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants
(clinicaltrials.gov)
- P1; N=78; Recruiting; Sponsor: Biogen; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • PCR
1 to 7
Of
7
Go to page
1